Comment
A fatal outcome in patients with giant cell arteritis has been poorly recognised, and previous reports have generally been case reports or necropsy studies. 4 The necropsy rate is low in many countries, and microscopic examinations of arteries in patients dying from vascular disorders are not routine, especially in elderly people. Hence, giant cell arteritis may be concealed among the cases currently diagnosed as ischaemic catastrophes due to arteriosclerosis.
There is a general consensus that all patients with giant cell arteritis should be treated with corticosteroids. As well as rapidly relieving clinical symptoms, such treatment may prevent ischaemic ophthalmic catastrophes.5 Our findings indicate that corticosteroids may also prevent other ischaemic lesions.
Our results show that patients with giant cell arteritis run an increased risk of dying from vascular disorders in the initial phase of the disease. After four months, following the start of corticosteroid treatment, the risk equalled that of the general population. Traditional treatment entails patients staying in hospital long term, which is costly, and repeated assay ofdrug concentrations to avoid toxicity in patients who are likely already to have impaired renal function. We report on two patients with malignant external otitis who were treated with oral ciprofloxacin.
Case reports
Case I-A 61 year old man with diabetes controlled by diet was referred with a 24 day history of a painful, discharging right ear. Previous treatment with amoxycillin, flucloxacillin, and gentamicin given systemically had proved ineffective. Examination showed profuse meatal granulation. His facial nerve function was intact. A technetium-99m radioisotope scan (figure) showed increased uptake in the right mastoid. A computed tomogram showed soft tissue filling the external meatus, middle ear, and mastoid process and bony sequestration. A meatal swab grew P aeruginosa that was sensitive to all antibiotics that are effective against pseudomonas, including ciprofloxacin. within two days. After seven days he was discharged taking ciprofloxacin and co-proxamol. After 21 days he was free of pain and had no meatal granulations, and a meatal swab yielded no growth. Treatment was stopped after nine weeks, and after five months he remained free of disease. Case 2-A 72 year old insulin dependent diabetic was referred with a 10 week history of otorrhoea of the left ear and a two week history of facial swelling on the left side. Oral amoxycillin had produced no improvement. Examination showed a fluctuant preauricular swelling, purulent otorrhoea, and extensive meatal granulations. His facial nerve function was intact. A 'Tc radioisotope scan showed increased uptake in the mastoid and preauricular region. A computed tomogram showed soft tissue filling the meatus and the air cells of the mastoid, a low attenuation mass deep to the masseter and temporalis muscles, and obliteration of the fat planes of the infratemporal fossa. A meatal swab grew P aeruginosa. The meatus was debrided and the preauricular swelling aspirated. Treatment was started with oral ciprofloxacin (750 mg twice daily) and insulin. After three weeks he was discharged taking ciprofloxacin, and meatal swabs yielded no growth. Treatment was stopped after 10 weeks, and after five months he remained free of disease.
Comment
There are few reports of treating malignant external otitis with ciprofloxacin, and in none of these was the drug used orally as the only antibiotic. Treating otitis with oral ciprofloxacin is an important advance in managing this disease as it obviates the necessity for patients to stay in hospital long term to receive antibiotics intravenously and eliminates the risks of secondary ototoxicity and nephrotoxicity associated with traditional treatment. We do not know whether a lower dose than 750 mg twice daily would suffice, but as malignant external otitis has a reported mortality of 35% (51% when a facial palsy develops and 75% when multiple cranial nerve palsies develop)' it seems reasonable to use high doses of a well tolerated drug with few side effects. Their ages ranged from 20 to 91, and 108 were men. The hospital records of these patients were examined to determine the number who had first degree relatives with myelodysplasia. To eliminate bias due to case finding relatives were not screened for myelodysplasia unless two family members were known to be affected or they had a history of anaemia, excessive bleeding, or recurrent infections. Because the frequency with which myelodysplasia is diagnosed seems to be increasing4 we excluded relatives in whom the disease was diagnosed before or after the registration period.
We identified five people with myelodysplasia among the first degree relatives of four patients who were already on the register. The four patients and their relatives comprised two pairs of parent and child, Expected number offirst degree relatives with myelodysplasia during six years ofstudy 
An increased incidence of myelodysplasia in the families of patients with myelodysplasia has not been reported before, but previous reports have described individual affected families.' This hospital serves as a referral centre for a population of about 1-4 million people, and the annual incidence of 23 per million each year is comparable with a previous estimate.4
Explanations of the increased incidence of the disease in relatives of patients might also account for the increased incidence of non-haemopoietic malignancies in patients with myelodysplasia.2 It has been suggested that inheritance of rare alleles at the locus of the Ha-ras oncogene is linked to a susceptibility to malignancy, including myelodysplasia, but this has not been confirmed in two larger series of patients with myelodysplasia.5 The increased familial risk of myelodysplasia might be the result of common environmental factors or inheritance, or both. BMJ VOLUME 299 26 AUGUST 1989
